Health

Universal Health Services, Inc. UHS recently revised its 2022 outlook due to significant drawbacks in operations witnessed in the first two months of the second quarter. Following the announcement, the stock declined 6.1% yesterday. The more...

Investors in Sensus Healthcare, Inc. SRTS need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 15, 2022 $2.50 Call had some of the more...

PRINCETON, N.J., July 01, 2022 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women’s healthcare company, today announced the pricing of its upsized public offering of an aggregate of more...

BIOLASE ENTERS INTO FAVORABLE CREDIT AGREEMENT AMENDMENT PR Newswire LAKE FOREST, Calif. , June 30, 2022 /PRNewswire/ — BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced that, on June 30, 2022 , more...

DUBLIN, Ireland, June 30, 2022 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the more...

TORONTO, June 30, 2022 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2022 financial results will more...

Conference Call Scheduled for June 30, 2022 at 11:00 am EASTERN DUBLIN, Ireland, June 29, 2022 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and more...

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) today highlighted a peer reviewed journal article featuring the HTG Transcriptome Panel (HTP) less than one year after the breakthrough product’s commercial release. Shares of HTG Molecular Diagnostics, Inc. more...

Investors interested in stocks from the Medical – Drugs sector have probably already heard of Assertio (ASRT) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck more...

Jazz Pharmaceuticals JAZZ announced that its phase III study — RELEASE MSS1 — evaluating nabiximols oromucosal spray (Sativex in ex-U.S. markets) for clinical measures of spasticity in individuals with multiple sclerosis (MS) failed to meet more...